We are beyond proud to see our portfolio company SpyBiotech take their Covid-19 vaccine to human trials alongside the Serum Institute of India. What a great day for their team, for science, and for the world at large.
SpyBiotech’s unique protein superglue technology could become a powerful new tool in the fight against infectious diseases and cancer. The success of this trial would provide a meaningful indication of that. As their CEO, Sumi Biswas, says, “our technology can be combined with multiple vaccine delivery platforms to create a plug and display vaccine which is critical for generating vaccines rapidly and safely.”